Track Orphazyme A/S's total liabilities ($1.8M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest total liabilities for ORPHY is $1.8M as of June 2024. That compares with $7.3M in the prior-year period — down 75.9% year over year. Investors often review this figure alongside Orphazyme A/S's historical trend and sector peers before judging valuation or financial health.
Over the past year, ORPHY's total liabilities moved from $7.3M to $1.8M — a 75.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Orphazyme A/S's operating scale or balance-sheet position.
A total liabilities figure of $1.8M for ORPHY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting ORPHY's total liabilities ($1.8M), review year-over-year change from $7.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Orphazyme A/S's total liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.